Table 1

Characteristics of patients at initiation and 12-week follow-up

Clinical dataAt initiationAt 12-week reviewComparative p value
ESR, median (IQR)16 (7.5–31.3) (n=40)5 (2.25–10) (n=26)p=0.0009
CRP, median (IQR)5.5 (2–21.3) (n=40)1 (1–2) (n=27)p=0.0004
Albumin, median (IQR)35 (30.8–38) (n=40)38 (36–41) (n=27)p=0.002
Calprotectin, median (IQR)840 (618.3–1642.5) (n=34)250 (60–760) (n=17)p=0.008
wPCDAI, median (IQR)27.5 (7.5–55) (n=29)5 (0–20) (n=21)p=0.002
PUCAI, median (IQR)45 (40–55) (n=11)23.8 (8.1–60) (n=6)p=0.4
Disease classification (Crohn’s)
% (n/N)
Remission, 28% (8/29)Remission, 67% (14/21)p=0.002
Mild, 31% (9/29)Mild, 28% (6/21)p=0.9
Moderate, 28% (8/29)Moderate, 0% (0/21)p=0.02
Severe, 13% (4/29)Severe, 5% (1/21)p=0.6
  • CRP, C reactive protein; PUCAI, Paediatric Ulcerative Colitis Activity Index; wPCDAI, weighted Paediatric Crohn’s Disease Activity Index.